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Genomic testing for a genetic diagnosis is becoming standard of care for many children, especially those with a syndromal intellectual disability.
While previously this type of specialised testing was performed mainly by clinical genetics teams, it is increasingly being ‘mainstreamed’ into
standard paediatric care. With the introduction of a new Medicare rebate for genomic testing in May 2020, this type of testing is now available
for paediatricians to order, in consultation with clinical genetics. Children must be aged less than 10 years with facial dysmorphism and multiple
congenital abnormalities or have global developmental delay or moderate to severe intellectual disability. This rebate should increase the likeli-
hood of a genetic diagnosis, with accompanying benefits for patient management, reproductive planning and diagnostic certainty. Similar to the
introduction of chromosomal microarray into mainstream paediatrics, this genomic testing will increase the number of genetic diagnoses, how-
ever, will also yield more variants of uncertain significance, incidental findings, and negative results. This paper aims to guide paediatricians
through the process of genomic testing, and represents the combined expertise of educators, clinical geneticists, paediatricians and genomic
pathologists around Australia. Its purpose is to help paediatricians navigate choosing the right genomic test, consenting patients and under-
standing the possible outcomes of testing.
Paediatric genetic disease accounts for 2–14% of all hospital
admissions1 and has a high financial, societal and health-care
burden.2 Identifying a genetic diagnosis via genetic or genomic
testing (GT) enhances management and, in almost one-third of
cases, directs specific treatment or a change in care.3 In addition,
it allows recurrence risk estimation, enables the identification of
at-risk family members, shortens the diagnostic odyssey, reduces
invasive investigations and provides psychosocial benefits, includ-
ing closure for families.4
GT, which examines the DNA sequence of a patient’s genes, is
becoming a standard part of clinical practice, and as a result, the
number of patients receiving a genetic diagnosis has increased in
recent years. This type of testing, once mainly performed in the
clinical genetics clinic, is now being ‘mainstreamed’ into general
paediatric practice, with the introduction of a Medicare rebate for
patients aged 9 years 11 months or less with suspected mono-
genic conditions (Medicare Benefits Schedule (MBS) item num-
bers 73358–73361; Fig. 1).5
Next generation sequencing (NGS), also known as massively par-
allel sequencing, enables the simultaneous sequencing of millions of
bases of DNA. This tool has transformed the diagnostic landscape
and identifies the monogenetic aetiologies of neurodevelopmental
and multiple congenital anomaly (MCA) syndromes. Current diag-
nostic yield from GT is 29–57% in paediatric patients suspected of
having an underlying monogenetic condition.6
With the widespread adoption of NGS, the range of genetic
and genomic tests available to clinicians has expanded. This has
been accompanied by decreasing cost as more enhanced testing
platforms evolve. Historically, access to whole exome sequencing
(WES; protein-coding DNA) and/or whole genome sequencing
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(WGS; all DNA) has been limited, largely due to cost and the
availability of public funding.
With the introduction of this new Medicare item, paediatricians
will need to become familiar with the process of GT, including:
(i) recognising when and in which patients testing is clinically
warranted; (ii) fulfilling pre-test requirements; (iii) choosing and
organising the appropriate test, and obtaining informed consent;
and (iv) understanding, interpreting, and explaining results.
We present advice from Australian clinical genetics experts to
assist paediatricians in utilising the Medicare items.
Recognising when GT is indicated
Patient selection
Recognising that a patient warrants GT is critical and depends on
various factors. Firstly, the Medicare item numbers are only
applicable to patients seen in the outpatient setting. Secondly,
diagnostic yield is an important consideration and is largely
related to the patient’s phenotypic presentation (Fig. 1). Specific
patient cohorts have a higher likelihood of a monogenic disorder,
such as those with dysmorphism, moderate–severe intellectual
Fig. 1 Suggested pathway for genomic testing under Medicare Benefits Schedule item 73358.
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disability (ID) and MCA.7,8 Patients with isolated abnormalities
(e.g. single organ involvement such as cleft palate, isolated
autism or attention-deficit/hyperactivity disorder or dysmorphism
without significant co-morbidities, or milder delay, will not qual-
ify for testing, due to low yield and the complex/multifactorial
nature of these conditions.9–12 Conversely, GT is indicated in
some clinical presentations (e.g. congenital hearing loss, neurofi-
bromatosis type 1) even though these patients do not qualify for
the rebate. In these instances, referral to the local genetics service
is recommended per usual practice, especially if there are issues
such as reproductive planning.
Requirements before testing can be ordered
First-tier testing
Genomic analysis is an expansive and expensive test; therefore,
routine first tier investigations should not be overlooked (Fig. 1).
These include clinical assessment, history, and routine blood test-
ing (e.g. electrolytes, full blood count, thyroid function, creatine
kinase and liver function tests); chromosomal microarray (CMA)
testing (consistent with MBS item 73 292)5 must also have been
performed and be non-informative. CMA screens the patient’s
chromosomes for microdeletions and microduplications, also
known as copy number variants (CNVs). These are found in
5–15% of children with ID or global developmental delay
(GDD).13,14 CNVs cannot currently be detected using WES, mak-
ing this first step critical to ensure pathogenic CNVs are detected.
Ordering CMA is now part of routine paediatric practice and will
not be further discussed; useful references15,16 and a testing
guide17 are available.
Although not specified by the item descriptor, including Fragile
X testing (FRAXA) and urine metabolic screen in first tier testing
may be warranted, given that FRAXA accounts for 2% of non-
syndromic ID18,19 and metabolic conditions underlie 0.8–1.8% of
GDD, some of which are treatable.19–21 CMA, FRAXA and urine
metabolic screen together provide a diagnosis for up to 15–20%
of GDD/ID.22
Consideration of patient perspectives
It is essential to ensure that the clinician’s and family’s motiva-
tions for testing are aligned. A genetic diagnosis may have clinical
utility: guiding management, avoiding invasive investigations and
ending the diagnostic odyssey. Cost-effectiveness and increased
sensitivity when compared to sequential standard testing has also
been proven.23,24 For the patient and their families, it may pro-
vide closure, enable easier access to services, facilitate reproduc-
tive options and allow interaction with an empathetic
community via patient support/advocacy groups.
However, the psychosocial implications for a family in attaining
a genetic diagnosis cannot be underestimated. A genetic diagnosis
may represent a further loss of hope for families already caring for
a child with significant medical and intellectual issues, given that
such conditions are generally life-long and in most neu-
rodevelopmental disorders, leave little hope for cure. Clinically,
rare genetic diagnoses often have scant natural history informa-
tion. Genomic data filtering is still evolving; and therefore families
may receive unclear or unexpected results that create uncertainty
and anxiety, and this needs to be discussed carefully as part of the
consent process. For some communities, there is guilt and cultural
stigma associated with a genetic diagnosis.25,26 Further, the fear of
uncovering unexpected family relationships such as non-paternity
may deter some families. The insurance implications of a genetic
diagnosis may also be a consideration regarding concerns around
privacy of clinical and laboratory databases.
Organising genomic testing
Consent
The above are important considerations for the paediatrician and
family during the consent process, which is the first step in
organising a genomic test. Consent is mandatory. Ethically, it
applies to personal autonomy and self-determination. Moreover,
Australian laboratories are required to ensure that written
informed consent has been obtained prior to proceeding with
GT. These consent forms may be accessed via local clinical genetic
services, which are listed on the CGE website.27 At the time of
writing, a National Consent template is in development under
the National Implementation Plan for the National Health Geno-
mics Policy Framework, for adoption and adaptation across all
Australian jurisdictions.
Informed consent requires a relevant summary of genetics for
patients and explanation of possible outcomes to help manage
patient/parent expectations. The main possible outcomes of test-
ing can form the basis of the consent discussion (Fig. 1, Table 1).
Printable resources for patients explaining genomics are available
online.35–37
Apart from potentially predictive and/or unwanted health
information being inadvertently disclosed, the possible impact of
informative GT results on insurance must be noted to families. A
5-year moratorium was implemented by the Australian Financial
Services Council regarding use of genetic data to determine insur-
ance premiums6,38; however, some insurers may require relevant
GT results be disclosed with new applications for mortgage/
income protection/life insurance.6 It is important to reassure par-
ents that GT results have no impact on obtaining health insur-
ance in Australia, or on insurance policies already in place. More
information is available online.38
Discussion with a Clinical Geneticist
Ordering GT under Medicare item 73 358 requires discussion
with a clinical geneticist. The exact format of this is not specifi-
cally defined, and therefore discussion with the local genetics ser-
vice is suggested, as each genetics unit will have developed their
own protocol to facilitate testing. Written evidence of appropriate
consultation should be submitted to the laboratory with the test
request and patient consent forms, to ensure claims are not
rejected because they do not meet the requirements of the Medi-
care Item number.
Which test to order
Interrogation of a patient’s genome can be undertaken via vari-
ous approaches, including WGS, WES, gene panel and single
gene sequencing. Choosing the appropriate test requires an
understanding of the types of GT (Table 1).
ID, severe epilepsy and some MCA presentations are geneti-
cally and phenotypically heterogeneous, that is the clinical
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Table 1 Types of genomic testing and possible outcomes of testing
Term Explanation Additional considerations




WGS utilises next-generation sequencing
(NGS) to sequence the entire genome
including the exons, introns and intergenic
regions, and even the mitochondrial
genome
This has the highest yield, but also generates the most data for
analysis. It also allows for accurate copy number (deletion/
duplication) analysis. To maximise diagnostic yield and assist
interpretation of VUS, a trio WES or WGS is highly





WES utilises NGS to sequence all coding
regions of genes. This does not include the
intergenic regions or deep introns and may
not include the mitochondrial genome
See above considerations
WES sequences only the exons, or protein coding regions of the
genome, as well as the immediately adjacent intronic sequence
in which variants affecting mRNA splicing may be identified.
This includes approximately 50 million base pairs of DNA or
2.8% of the genome
Gene panel A particular predefined subset of genes is
analysed, either in its own genomic test or
as a part of WES or WGS
It may be appropriate to only examine the specific genes related
to the clinical presentation. For example, in Noonan syndrome,
there are approximately 20 causative genes reported to date.
Therefore, examination only of those genes that are associated
with Noonan syndrome is undertaken
Single gene
sequencing
Conventional Sanger sequencing of a single
gene
When the diagnosis is both clinically and genetically
homogenous (e.g. Cystic Fibrosis and the CFTR gene),
sequencing the single causative gene may be undertaken.
Whilst WES/WGS and tests are covered by the new Medicare
item number, to date most single gene tests are non-rebatable
and should be discussed with or referred to the local genetics
services
Possible outcomes of genomic testing
Genetic cause
identified
A likely pathogenic or known pathogenic
variant in a disease gene associated with
the subject’s phenotype has been found
A genetic cause is identified in 29–57% of cases7,8 and may
provide additional information on the patient’s condition, family
recurrence, and, possibly, management and future prognosis.
Additional information may be required to help inform the






These are seen in up to 20–25% of cases28,29
and may cause confusion and anxiety. A
VUS result may be returned when there is
insufficient evidence that an identified
variant is the cause of the patient’s
condition
A VUS should not be used in clinical decision making, and may
need further discussion with local genetics services, the
laboratory, and even further research and time to clarify.
Parental studies may be helpful to determine if a VUS is benign
or pathogenic, and this is why doing a trio analysis upfront is
so helpful. If the variant is inherited from an unaffected parent
it may be considered less likely to be causative. Guidance on
setting expectations including possibility of VUS results is
provided on the CGE website30
Incidental
finding (IF)
A finding that is unrelated to the initial
indication of testing, but is of possible
clinical importance. Examples include a
cancer predisposition gene, or unrelated
genetic condition such as Cystic Fibrosis
carrier status. Mathematical modelling
estimates their frequency to be 1.5–6.5%,31
while studies suggest that they are seen in
1–2% of tests conducted internationally32,33
The implications associated with finding Ifs may be concerning
for the patient or to the parents themselves. However, it is
vital to highlight that most diagnostic genomic analysis is
patient-specific and phenotype-focused, and therefore this
approach will largely mitigate the risk.
The identification and reporting of Ifs is a controversial area and
raises additional issues such as insurance and screening. The
Australian approach to Ifs differs from that in the USA where
the American College of Medical Genetics recommends
screening a certain set of ‘medically actionable’ genes (termed
secondary findings) and recommends reporting of all Ifs.32
Such a practice facilitates surveillance or treatment in a
person’s lifetime. However, this approach is controversial and
currently not standard practice within Australian genomics
laboratories
(Continues)
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presentation may be associated with any one of potentially hun-
dreds of genes. For childhood syndromes or ID/GDD, WES or
WGS are the tests of choice as they offer a broad, agnostic screen.
At the time this report was written, WES is more widely available
and is less expensive than WGS. This will evolve in the future as
WGS becomes more logistically and financially accessible.
When ordering WES or WGS, whether to test the patient in iso-
lation (singleton testing; MBS item number 73358) or along with
both biological parents (trio testing; MBS item number 73359) is
an important consideration. The latter (trio) approach is highly rec-
ommended given it simplifies analysis. Parental sequencing is used
to triage inherited variants of interest in the sequencing data,
therefore improving laboratory reporting efficiency and diagnostic
yield.39,40 It is also a more streamlined clinical test as trio testing
identifies fewer variants of uncertain significance (VUS; Table 1)
than singleton testing. However, in some instances only one par-
ent is available for testing, or parents may have reservations about
genomic sequencing of their own data because of privacy or insur-
ance implications and a singleton may be undertaken.
When organising a trio-based genomic test, consent must be
obtained from both biological parents and for the child. A cau-
tious and inclusive approach needs to be undertaken where par-
ents are separated or divorced, and discussion with both parents
is recommended.
Most laboratories will require DNA to be extracted from a
blood sample (4–10 mL EDTA), while some laboratories will also
offer GT with DNA extracted from buccal swabs or saliva samples.
Discussion with the testing laboratory and local genetics services
is recommended.
Choice and prerequisites of laboratory
Testing must be done by a National Association of Testing
Authorities (NATA)-accredited Australian laboratory, and the
choice of laboratory will often be determined by location and
availability. Discussion with the local genetics unit may be
required. Testing by international laboratories is not funded
through Medicare.
Most Australian states have local institutional molecular laborato-
ries, which will have specific requirements and documentation that
must be fulfilled prior to ordering GT (Fig. 1). Many will require a
copy of the consent: one for the patient and one each from the par-
ents if a trio WES/WGS is being requested. In addition, detailed
clinical or phenotypic information is critical to genomic analyses.
Although a national referral form is being developed, at present
each laboratory will have its own specific phenotype form and often
a separate laboratory-specific request form may also be needed for
the patient. Relevant family history and the phenotypic details of
the patient should be clearly summarised, as this will inform the
genomic analysis. Occasionally, a parent has a similar phenotype to
the patient, and this needs to be taken into account when variants
are analysed. It is essential to provide such information to the labo-
ratory at the time of ordering. The use of standardised nomencla-
ture such as Human Phenotype Ontology terms41 is recommended
when detailing the phenotype as these are utilised to examine
genomic data. Human Phenotype Ontology is a dynamically curated
resource of standardised phenotypic terminology that provides a
useful interface between the disciplines of genomic and clinical
medicine, thus enabling tailored data interrogation.
Return of results
GT is often complex and results may take weeks to months
depending on local laboratory availability, though expedited
options are available on request in some laboratories. As GT is
integrated into mainstream paediatric practice, general paediatri-
cians will become more comfortable with explaining possible
results (Fig. 1 and Table 1). However, the conditions being diag-
nosed are often rare, and VUS or incidental findings (IFs) may be
challenging to communicate to families (Table 1).42 Ideally,
results disclosure should have a nuanced, tailored approach and
may be dependent on the family’s and clinician’s genomic liter-
acy. If pretest counselling as part of the consent process has been
comprehensive, the family usually has a relatively good under-
standing of the genomic process and can grasp the complex con-
cepts of genomic results.42 Printable fact sheets for patients
explaining VUS, IF and uninformative results are available.43
A confirmed genetic diagnosis may be straightforward with
easy access to medical information regarding natural history, co-
morbidities and therefore management. More often, given the
genetic heterogeneity of ID, the causative gene is uncommon and
further information for both the clinician and family may be
Table 1 (Continued)
Term Explanation Additional considerations
Negative result No causative variant is found. Possible
explanations are:
1 The underlying cause is not monogenic; it
may be oligogenic or polygenic; the former
is hypothesised to be the case in some
patients with autism, explaining the lower
diagnostic rate9–12
2 The causative variant is in an as yet
undiscovered gene
3 The variant is not detected due to
technical limitations of the test
4 The condition is not genetic
Given gene discovery is dynamically occurring, with 300 novel
genes identified per year,34 re-examination of genomic data in
1–2 years will have increased yield. It is also important to
consider additional causes of genetic conditions that will not
be diagnosed on standard genomic testing, such as
mitochondrial variants, methylation/ epigenetic alterations,
deep intronic variants, repeat expansion disorders, and cryptic
copy number variants. These can be discussed with local
genetics services
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obtained through the local clinical genetics unit or via the
referenced resources.43 If a trio test has been undertaken, recur-
rence risk may also be clarified. If a singleton test was conducted
and a parent or sibling is also suspected to be affected, a Medicare
rebate is available to test for the causative variant in nuclear fam-
ily members (Items 73361, 73362). This may require pre and
posttest guidance from the local genetics services.
In the event of a VUS, consultation with clinical genetics is
helpful, as further detailed phenotyping or functional studies
may be required to clarify whether the change in the specific
gene fits with the clinical presentation reported in the literature.
In explaining a negative or rather an uninformative result, it is
important to highlight to families that regular re-analysis of data
can provide an additional diagnostic yield of 10–15%, due to the
ongoing discovery of new gene-phenotype relationships.23,44 This
is recommended every 18 months,44 has been assigned a Medi-
care item number (Item 73360), and is available twice after the
initial test. This should also be discussed with the local genetics
services, especially if there are mitigating circumstances that war-
rant a faster reanalysis (e.g. in the event of a pregnancy or pro-
gressive disease). Some conditions are not detected by WES;
these include balanced disease-causing rearrangements, mito-
chondrial variants, methylation abnormalities (as underlies
Angelman and Prader-Willi syndromes) and small structural
variants such as deletions/duplications; the latter are below the
resolution of CMA but could potentially be diagnosed by WGS.
Conclusion
GT will increasingly be integrated into mainstream paediatrics, and
a suggested pathway to streamline the process for any child whose
clinical features meet the Medicare requirements is outlined in
Figure 1. However, complex issues may arise, including consent
matters, logistics of ordering testing, result interpretation and expe-
diting testing in the event of a pregnancy or a management con-
cern. There may also be a number of potential sources of
uncertainty for the family arising from GT.45 The involvement of
the genetic counsellor has been proven to be associated with better
patient-reported outcomes.34,46,47 ‘Embedding’ a genetic counsel-
lor within a specialty that routinely uses GT is a model of care that
is being evaluated. Access to local genetics service is recommended
at any time during the process and an expanding list of resources
is being developed to help clinicians and families understand,
implement and streamline GT, both now and in the future.43
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